# Allergy Therapeutics plc PQ Birch Phase III clinical trial completes recruitment

- Link: https://www.directorstalkinterviews.com/allergy-therapeutics-plc-pq-birch-phase-iii-clinical-trial-completes-recruitment/412743303
- Published: 2018-01-09T07:14:02+00:00
- Author: Giles Arbor

**Allergy Therapeutics plc** ([LON:AGY](https://www.directorstalkinterviews.com/company/allergy-therapeutics/agy.l)),
the fully integrated specialty pharmaceutical group specialising in allergy vaccines,
today announced that recruitment of the Group’s Phase III clinical trial with PQ
Birch (PQBirch301) has been completed as expected. The PQBirch301 study is a pivotal
Phase III study designed to evaluate the safety and efficacy of the Group’s ultra-
short course, convenient for patients, aluminium free PQ Birch subcutaneous immunotherapy
to address the cause of symptoms of allergic rhinoconjunctivitis due to birch pollen.

The PQBirch301 study has randomised over 560 patients from 59 centres in four European
countries: Germany, Austria, Poland and Sweden. The primary efficacy data will be
assessed during the birch pollen season of 2018 and the results of the trial are
expected during H2 2018. The successful completion of this pivotal Phase III study
would fulfil the requirements for PQ Birch under the Therapieallergene-Verordnung(
TAV) of the Paul Ehrlich Institut before anticipated marketing authorisation.

PQ Birch is one of a number of ultra-short course, subcutaneous immunotherapy products
in clinical development for various allergies, and these form a key component of
the Group’s three-pillar growth strategy. This includes: developing a strong pipeline
facilitated by investment from the growing, profitable European revenue stream; 
expanding the existing European business; and preparing for product entry into the
US market. The PQ family of products complement the Group’s existing European marketed
portfolio of convenient short course subcutaneous immunotherapy products and are
particularly suited to the changing regulatory environment for allergy products 
in the US

Approximately 6% of the population of Europe alone is allergic to birch pollen1 
and there continues to be a need for a safe and well tolerated effective treatment
for this significant health issue.

> **Manuel Llobet, Chief Executive Officer of Allergy Therapeutics Plc, commented:**“
> The completion of recruitment in our pivotal Phase III clinical study with PQ 
> Birch is an important milestone for the Group. Marketing authorisation of the 
> first MPL-adjuvanted, ultra-short course aluminium free vaccine available to patients
> will strengthen the Group’s portfolio and help address the current unmet needs
> in allergy.”

Share on:
